Single administrations of poly C or poly I are anti-viral against infections of encephalomyocarditis (EMC) and Semliki Forest virus (SFV) in mice but poly U and poly A are not. The degree of protection is dose-dependent and mice which die do so at a later time than untreated controls even in a strain of mouse in which the time of death is not dependent on the dose of virus given. No circulating interferon is found after treating mice with poly C or poly I even at polynucleotide doses which give the same degree of protection as the interferon inducer, poly I: C. Several additional features distinguish the protection by poly C and poly I from interferon induction : the effect is low 2 4 h before infection and maximal 6 h before infection, the effect is short-lived and mice do not show hypo-reactivation to repeated treatment. Limited treatment of mice with poly I:C, interferon or poly C before infection itself results in additional protection when poly C is also administered after infection, indicating that poly C has an effect after onset of virus replication. After infection poly C and poly I are both more effective by the intravenous route but before infection they are most effective when administered by the same route as the virus. Quantitative comparisons of the protective effects of poly C, poly I and the interferon inducer, poly I:C, are possible from dose response curves of the potynucteotides at different times relative to infection and by different routes of administration. The results are considered in relation to the presence of homopolyribonucleotide tracts in the viral genomes and effects on the reticulo-endothelial system of the mice.
INTRODUCTION
Polynucleotides are not generally considered to have anti-viral activity except by means of interferon induction. Single-stranded polynucleotides have been found to be poor inducers of interferon and then are only effective when they are highly structured or used under conditions which cause formation of multi-stranded structures (De Clercq & Merigan, I969) . Nevertheless there are several reasons for discounting this generalization on the basis of existing experimental data and in addition there are a priori arguments for the existence of anti-viral polynucleotides that do not necessarily induce interferon. In particular viral RNA (mRNA or genomic RNA) must include nucleotide sequences that are recognized by cellular factors necessary for replication of the virus and such sequences, if administered to an infected cell, could act as competitive inhibitors of virus replication. Encephalomyocarditis virus RNA, in common with many picornaviruses contains a poly C IP: 54.70.40.11
On: Fri, 11 Jan 2019 08:58:04 22 N. STEBBING, C. A. GRANTHAM AND N. H. CAREY tract (Porter, Carey & Fellner, i974) which is probably in the untranslated region (Porter et al. t974; J. S. Emtage, N. H. Carey & N. Stebbing, in preparation) . This poly C tract is single-stranded in native EMC virus RNA (Goodchild, Fellner & Porter, I975; J.S. Emtage, N. H. Carey & N. Stebbing, in preparation) and poly C is therefore a possible competitive inhibitor of EMC virus replication. Polynucleotide inhibitors of the type considered here have been reviewed by Pitha (I973) for the RNA bacteriophages and oncornaviruses. It is not possible to review critically here the very extensive literature on the anti-viral activity of poly I: C through induction of interferon. Nevertheless we consider that existing data does not rule out direct anti-viral activity of the single stranded homopolynucleotide components of poly I:C. In particular, preparations of poly I:C contain free singlestranded ends whose role in the overall anti-viral effect has not been elucidated. Moreover, poly I: C has been shown to exist partly in an open state involving long runs of separated base pairs that re-anneal surprisingly slowly (Teitelbaum & Englander, I975) . Thus, the formation of a double-stranded complex between poly C and poly I, while producing a moiety that induces interferon, could also allow direct effects of the component homopolynucleotides.
METHODS
Viruses. Encephalomyocarditis (EMC) virus, obtained from Dr I. Kerr, National Institute for Medical Research, Mill Hill, London, was grown in vitro in Krebs ascites tumour cells for I8 to 24 h and then, after centrifuging for I5 min at 2ioo g the supernatant fluid was stored at -2o °C in 5o% glycerol. Very little loss in infectivity was observed over many months. Before infection the glycerol stock was diluted in o.89% (w/v) NaCI, Io mM-HEPES, pH 7"5 (HBS) and o.I ml injected intraperitoneally or intravenously into one of the lateral tail veins of mice which had been warmed for I to 3 min in a box over a 6o W light bulb. One times LD100 was found to be approx. I5 to 2o times the LDs0 and the infectivity of intravenously administered virus was one tenth of the infectivity of intraperitoneally administered virus.
Semliki Forest virus (SFV) obtained from Dr Zwartouw, MRE, Porton, was passaged in mouse brains and a stock was obtained by homogenization of the brains of suckling mice infected intracerebrally. The crude stock, stored at -7o °C, was diluted in HBS and o.1 ml injected intraperitoneally within I h of thawing.
Polynucleotides. All polynucleotides were from P-L Biochemicals and obtained through International Enzymes Ltd, Windsor, Berks., U.K. The poly C used in these studies was all lot number 19I-I 5. Polynucleotides were made up in autoclaved HBS and used immediately or stored at -2o °C. Poly I was heated to 6o °C for I min before use in order to dissolve the polynucleotide.
Mice. LACA mice were obtained from Scientific Agribusiness Consultants (International) Ltd, Braintree, or Bantin and Kingham Ltd, Hull. Strain 129 mice and panel bred ASW mice (here designated V1 mice) were bred in our own animal breeding unit. Most experiments were carried out with female mice but no differences between sexes were found in the protective effects of polynucleotides here described. Alt mice used were between 6 and Io weeks old and weighed between I8 and 24 g. Before and after treatment and infection, mice were maintained at 22 °C with unlimited access to water and standard rat and mouse breeding diet from Grain Harvesters Ltd, Wingham, Kent, U.K.
Interferon. Crude mouse serum interferon was prepared 4 h after intraperitoneal administration of 60 #g poly I: C and stored at -20 °C.
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Mouse serum interferon was assayed by determining that serum dilution which gave 50% plaque reduction of EMC virus on L-929 cells grown in z5 cm 2 Falcon or Nunc bottles using BME medium (Flow Laboratories Ltd, Irvine, Scotland) with Io% calf serum (Flow Laboratories Ltd). The serum dilutions were made in BME medium at pH 7"5. Eighty-five ~o confluent cell sheets were infected ~6 to z 4 h after addition of dilutions of the serum to be assayed and the infected cell sheets were overlayed with o'7% agar (Purified agar from Oxoid Ltd, London) 3o rain later. Plaques were counted z days later after staining with Neutral Red.
Statistical methods. The time of death of individual mice was obtained from records of surviving mice prepared twice daily. Records were generally maintained for only 15 to 2o days after infection since less than 3 % of treated mice were found to die after this period. The time of death of a particular mouse was taken to be the first recorded time at which the mouse was no longer alive. The survival time was taken as the interval in hours between the time of infection and the recorded time of death. An average survival time for a group of mice was obtained by calculating the mean of the reciprocals of these times (t), taking the reciprocal for survivors to be zero. This mean was multiplied by IOO to give a value of approx. I for infected control groups (survival time of infected mice was about IOO h). These means of reciprocals are designated as values of I/t x I o ~. Treatment of infected mice, even in cases where control groups indicated doses over I x LD~0D, caused some mice to survive indefinitely and also prolonged the time until death of the others. Comparison of such controls and treated groups by analysis of variance did not prove justified since the variance ratios were too high. This arises from the fact that the ~/t values of groups containing survivors are not normally distributed, We therefore used the logrank method of Peto & Pike, 1973 , and include X ~ values with I degree of freedom calculated from the survival times in hours in the tables and text that follow. We wish to emphasise that juxtaposition of mean values of I/t x lO 2 and X 2 values does not imply that the X ~ values refer to reciprocals of the time of death or their means. Our justification for using values of I/t x I o ~ for comparative purposes lies in the fact that we have obtained a good correlation between significance levels determined by the logrank method and analysis of variance based on unequal variances. The mortality curves presented have been simplified by plotting survivors at only one time every day. The significance levels of X 2 values and Student's t-test values are indicated by asterisks as follows: ***, P < o.ooi ; **, P < o.oi ; *, P < o'o5. No asterisk indicates P > o'o 5 and is taken as non-significant.
RESULTS
Protective effect of polynucleotides intraperitoneally administered
The protective effect of poly C administered intraperitoneally to LACA mice in doses of 25o, 5oo and 75o #g against a wide range of virus doses is shown in Fig. I a. It is apparent that the degree of protection increases with increasing amounts of poly C and the effect decreases as the virus dose increases from I x LD10 o to Iooo x LD10o. Similar protection is found in strains iz 9 and Vl mice as shown in Fig. I b, c. The mortality curves in Fig. 2 show that the dose dependence of the protection afforded by poly C is particularly clear at virus doses below I x LD~00. This figure also shows that the mean time of death of EMC virus infected LACA mice does not vary much with the dose of virus used and this is reflected in the relatively constant value of I/t for virus doses above I x LDx00 shown in Poly I has also been found to be anti-viral when administered intraperitoneally in LACA, I29 and V1 mice. The protection afforded by intraperitoneal administration of poly C, poly I and poly I: C at various times relative to infection of LACA mice is shown in Fig. 3 . Logrank analyses showed that protection was significant at the 5 ~o level or less compared with the infected control, for poly C and poly I between -24 h and + 6 h and for poly I: C between -72 h and + 2 h, relative to infection.
Effect of prior interferon treatments on protection by poly C after infection
We show below that the protection by poly C and poly I is not associated with detectable production of interferon. Such protection is reminiscent of the anti-viral effects of the polycarboxylates (Billiau, Muyembe & De Somer, 197I) and raises the question whether the anti-viral effects of poIy C and poly i are achieved simply by inhibition of virus transport from the site of injection (the peritoneal cavity), as is the case with the polycarboxylates, or whether they affect replication of the virus at some stage after it reaches its primary site of infection. Billiau et al. (I97[) argued that a compound which merely affects virus transport will prove ineffective after infection in animals treated before infection with an agent known to slow down the rate of virus replication, the agents of choice being interferon inducers or interferon itself. We therefore adopted the reasoning and protocol of Billiau et al. (197[): we treated mice before infection with poly I : C at -24 h or crude interferon at -6 h and then examined the effect of poly C administered 2 h after the time of infection when poly C treatment alone is ineffective. The results, shown in Fig. 4 and 5a show that after prior treatment with poly I: C or interferon, poly C is anti-viral after infection. Moreover, poly C is effective after infection in mice pre-treated with poly I:C even by the intravenous route (Fig. 4a) . We conclude that the anti-viral effect of poly C is not simply due to inhibition of virus transport from the peritoneal cavity. If poly C really does affect virus replication at some stage after infection of the initial target tissues then poly C itself administered before infection should allow increased protection by a second dose of poly C after infection. That this is in fact the case, whether the second dose is given intraperitoneally or intravenously, is shown in Fig. 5 b.
These last results indicate that poly C can be effective after infection and by the intravenous route and lead to the next series of experiments described below. It should be noted first that such effects would only be expected at lower virus doses. In particular, poly C should protect against virus doses below I x LD100 since they should correspond to the effect of pre-treatment with interferon or poly I: C at the higher virus doses shown in Fig. 4 .
Protective effect at low virus doses of polynucleotides intravenously administered
To avoid direct inhibition of virus transport from the peritoneal cavity we administered poly C intravenously z h after infection at virus doses between I × LD100 and IOO × LD100. From the results shown in Fig. 6 and Table I istered intravenously and that this route is in fact more effective than intraperitoneal administration at low virus doses. To test whether poly C is intrinsically more effective by the intravenous route we treated mice at several times relative to infection by both routes and infected them by the intravenous route. The results, shown in Table 2 B show that poly C is more effective by the intravenous route when infection is also by this route.
It should be noted that the magnitude of the anti-viral effect of poly C after infection at virus doses below [ x LD100 corresponds to the protective effect of poly C observed in the experiments of the previous section in which infectivity had been reduced to levels below I x LDx00 by prior treatment with poly I: C, interferon or poly C itself (compare Fig. 6 c with Fig. 4a and b) .
From the results shown in Fig. 6 it appears that poly C treatment both increases the number of survivors in treated groups and delays the mean time of death of those that do not survive. Statistical confirmation of these points is provided by the analyses in Table [. The logrank analyses ( Table I A) show that there is overall protection in treated mice except by the intraperitoneal route at a virus dose of I00 x LD100. Also the mean time of death of non-survivors in poly C treated groups is significantly different from the infected control groups by Student's t-test analysis (Table I B) except by the intraperitoneal route at a virus dose of IOO × LD100 and the intravenous route of I x LD100, but in the latter case there is only one death in the treated group. The anti-viral activities of intravenously administered poly C, poly A and poly U at 2 4 and 6 h before and 2 h after infection are shown in Table 2A from which it is clear that significant protection is only manifested by poly C and poly I even though higher doses of the other polynucleotides were used. The anti-viral activity of poly C and poly I administered intraperitoneally were investigated in the same experiment as the intravenous administrations and the results, also shown in Table 2A indicate that before infection the intraperitoneal route is the most effective but after infection the intravenous route is more effective. The data in Table 2A shows that intraperitoneal administration of poly C and poly I are most effective 6 h before infection and the data shown in Table 2 A indicates that this is also the most effective time for intravenous administration of these polynucleotides.
It is conceivable that the anti-viral effect of poly C and poly I is due to their constituent mononucleotides or other products obtained by breakdown in vivo. However this seems unlikely since we have tested a number of the most likely breakdown products and none were effective, as shown by the data in Table 2C . The magnitude of the protective effect of poly 1 reported here was found to be very constant for a given dose and time of administration. On the other hand, the protective effect of poly C under comparable conditions varied between experiments. The cause of this variation is not clear since the same batch of poly C was used in all our experiments but may be attributable to the greater sensitivity of poly C to nucleases. 
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The interferon inducing and ' hypo-reactivation ' capacity of poly C and poly [
We have tested the ability of poly C and poly I preparations to induce interferon by analysing mouse serum samples obtained 4, 8, i2 and 24 h after intraperitoneal or intravenous administration of the polynucleotides. Serial o'5 log10 dilutions of serum were prepared and assayed for inhibition of plaque formation as described under Methods, the highest concentration tested being o'5 log10 dilutions of the sera. At this level of sensitivity no interferon was detectable in serum at any of the times tested, except for the poly I: C controls as shown by the assays in Table 3.  Table 3 also shows the degree of protection afforded by poly C and poly I:C injected intravenously in groups of mice infected in parallel to those used for obtaining serum. The poly C and poly I: C treated groups were infected 6 h after treatment. The values of 1It × Io ~ and X 2 show that very similar protection was achieved by the two treatments. We conclude from the results that the protection afforded by poly C 6 h before infection cannot be accounted for by induction of interferon since comparable protection was only afforded by pronounced levels of interferon induced by poly I: C. It should be noted that the pH of our serum samples was never reduced to a value of 2 and all forms of interferon should therefore have been detected (Salvin, Youngner & Lederer, I973) .
The ability to induce interferon by various polynucleotides in mice was lost after repeated stimulation with the polynucleotide but after such treatment mice remained refractory to infection for up to Io days (Ho, I973). The extent to which such 'hypo-reactivated' mice are protected against infection depends on the dose of polynucleotide administered on each occasion but this dose is less than the single dose, given z 4 h before infection, required to give the same degree of protection (Ho, I973). Thus, if the protective effect of poly C and poly I is by induction of interferon, repeated administration over several days before infection should be at least as effective as a single administration 6 h before infection. We adopted a pre-treatment schedule of daily treatment for 5 days followed by infection on the 7th day with an additional polynucleotide treatment 6 h before infection for some groups. The results, for intraperitoneal and intravenous administration of the polynucleotides, are shown in Table 4 A and B. Intraperitoneal pre-treatment over 5 days with poly I:C is completely protective for Ioo/~g doses and partially protective for IO/zg doses but pre-treatment with poly C or poly I was not found to be significantly protective compared with the HBS treated control by logrank analyses (X 2 values all indicated P>o.o5). It is apparent that pre-treatment with poly C or poly I alone is less protective than when an additional dose of these polynucleotides is also administered 6 h before infection (compare first and last columns of I/t x ~o ~ values in Table 4A ). Comparison of the first and second columns of I/t x Io 2 values in Table 4A (X 2 and significance levels are shown) demonstrates that pre-treatment of mice with poly C or poly I does not interfere with the protection given by a single dose of poly I: C 6 h before infection even when the pre-treatment regime involves doses of the polynucleotides (4oo #g) that are protective when given in a single administration 6 h before infection. The results in Table 4B show essentially similar results for intravenously administered polynucleotides.
We conclude that poly C and poly I do not cause a ' hypo-reactivated' response to protection by poly I: C and therefore that poly C and poly I do not act as interferon inducers. The small degree of protection which occurs on pre-treatment of mice with poly C or poly I may be due to very low levels of interferon induction but the principal protective effect of poly C and poly I administered 6 h before infection involves a different mechanism.
Quantitative comparison of the protective effects of poly C, poly I and poly I: C against EMC infections
Quantitative comparisons of the protective effects of poly C, poly I and poly I:C are complicated by the fact that the first two polynucleotides are most effective 6 h before infection and the last, 24 h before infection or earlier (see, for example, Fig. 3 ). Moreover, 
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poly C and poly I are most effective intraperitoneally before infection but after infection the intravenous route is always more effective (see Table 2A and Fig. 6 ). However, poly C is more effective before infection when administered intravenously if infection is also by the intravenous route (Table 2B ). In contrast, the difference in effectiveness between intraperitoneal and intravenous administration of poly I:C, although significant, is small (Table 2A) , Finally, poly C and poly I are more effective by the intravenous route after infection but the intraperitoneal route is more effective and up to higher virus doses, before infection if infection is also by this route. A full range of quantitative comparisons of the relative efficacies of poly C, poly I and poly I: C would therefore require a laborious concurrent investigation of intraperitoneal and intravenous administration of these compounds over a range of virus doses. Even supplied with such data, it would seem impossible to give a single statement that would adequately compare the relative efficacies of any two of the polynucleotides. We have therefore restricted ourselves to presenting the necessary data and making limited comparisons.
The protective effect of various doses of poly C over a range of virus doses is shown in Fig. 7 . We note that in contrast to poly C, which shows no marked discontinuities in its protective effect with increasing doses (Fig. 8 b) , the protective effect of poly I tends to saturate as the dose reaches ioo #g. Moreover, as the dose of poly I increases above about Ioo #g, the protective effect decreases significantly. This result is not quite so apparent in the data shown in Fig. 7 as in other experiments, not shown here. However, Fig. 7 provides a comprehensive comparison of the protective effect of poly I given intraperitoneally and intravenously and shows that, compared with poly C, there is less difference in protection by the two routes of administration over a range of virus doses and poly I doses shown. Fig. 8 shows a comparison of poly C and poly I:C both administered intravenously at their optimum times (6 and 24 h before infection respectively) at four different virus doses, from which it appears that poly C does not compare favourably. However, it should be remembered that poly C would have been better intraperitoneally and poly I would also have been better by either route (see Table 2 A). Fig. 9 shows a comparison of poly C and poly I:C on two occasions before and once after infection and demonstrates the greater efficacy of poly C after infection. Poly I is also effective after infection (see Table z ) so the two single-stranded polynucleotides could prove therapeutically useful. In this respect it is instructive to compare the protective effects of poly C, poly I and poly I:C at 2 h after infection taking into account their acute toxicities which we have estimated at 24, I6 and I mg/2o g mouse (N. Stebbing, C. Grantham & N. H. Carey, unpublished results) . At 2 h after infection approximately comparable protection is obtained with 4oo, 2oo and Ioo #g of the three polynucleotides respectively, giving relative therapeutic indices of 6o, 8o and IO and demonstrating some advantage of the single-stranded polynucleotides.
Protection of mice against SFV by polynucleotides
We show in Fig. 1o the protective effect of 400/zg poly C administered intraperitoneally and intravenously 6 h before infection of LACA mice with SFV at doses from just less than I × LD~00 to just less than Ioo × LD~0 o. Poly C was also administered intraperitoneally and 
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intravenously at 2 h after infection but then only proved significantly protective at the lowest virus dose (Fig. Ioc) . Comparison of Fig. 6 and ~o shows that poly C is less protective against SFV than EMC virus. We have examined the protective effect of other homopolynucleotides and the results, in Table 5 , show that poly C and poly I are both protective while poly A and poly U are not. It should be noted that where treatment with poly U shows a significant X 2 difference in mortality compared with the infected controls, the poly-U-treated groups show increased mortality and not protection against infection. Although the protective effects of poly C and poly I are less pronounced against SFV than against EMC virus the protection is similar in terms of the time of maximum protection and routes of administration. Table 5 . Single-stranded polynucleotides have not generally been considered capable of inducing interferon and in those cases where significant induction has been shown the effect is generally small compared with double-stranded polynucleotides (see review of Colby, I97 Q. Ordered secondary structure in single-stranded polynucleotides has been considered necessary for induction of interferon such as has been found in poly I or in solutions of poly C when the pH is lowered (De Clercq & Merigan, I969). Baron et al. (I969) , claim that some preparations of poly C and poly I, particularly those from P-L Biochemicals, induce interferon with ~o% of the efficiency of poly I:C although this ability varies with the soIution used. They provide good evidence that this effect is not due to contamination causing double-stranded regions but unfortunately the authors do not indicate the solvent used for the polynucleotides or whether the difference in the 6 preparations tested was in the solvent or other factors. Baron et al. (I969) found that the kinetics of appearance of serum interferon in rabbits after administration of poly C, poly I and poly I: C is the same. Our results show no dectectable serum interferon in mice in the 24 h following administration of poly C or poly I, while poly I: C caused production of easily detectable levels of interferon in this time when doses of poly C and poly I: C giving equal protection were used.
Comparison of the protective properties of polynucleotides against SFV infection of LACA mice~
Whether or not some interferon is induced in our treatments with poly C and poly I, other experimental evidence shows that this mechanism is not a major factor. Although protection may be quite substantial, it is very short-lived with poly C and poly I and the maximum response time is 6 h before infection while poly I: C gives longer protection and is maximally effective 24 h before infection, or earlier. Also poly C and poly I did not cause the response to poly I: C to be ' hypo-reactivated' as would be anticipated for pre-treatment with a genuine interferon inducer. The effectiveness of poly C and poly I after infection cannot be reconciled with interferon induction since only high concentrations of good interferon inducers are protective when administered after infection and poly C and poly I are certainly not in such a category. It is not reasonable to argue that poly C and poly I induce circulating interferon much later than the period over which we assayed (24 h) since the single-stranded polynucleotides have a maximum response time much nearer the time of infection than poly I: C. On the other hand, if significant amounts of interferon are induced very soon after administration of poly C and poly I (within 4 h say) its rate of disappearance would have to be abnormally rapid compared with interferon induced by poly I: C to explain our results. This would seem unlikely from the results of Baron et aL (I969), discussed above.
There is evidence that normal macrophage activity is the major defence mechanism of the adult mouse preventing infection by Coxsackie B-3 (Rager-Zisman & Allison, I973) and limiting infection by yellow fever (Zisman, Wheelock & Allison, I97I ) and herpes virus (Hirsch, Zisman & Allison, 197o) . We believe that the difficulty of demonstrating anti-viral activity of poly C and poly I in tissue-culture (unpublished data) and the involvement in vivo of adult macrophages are the major reasons why the effects reported here have not been observed before. Details of macrophage activation in the anti-viral effects of poly C and poly I and the probable involvement of these compounds in stimulating the immune systems of the mouse against virus infection are currently under study.
